Meningioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Results of the meta-analysis indicated that high expression of Ki-67/MIB-1 may serve as a useful biomarker for poor prognosis in meningioma patients.
|
31679269 |
2019 |
Meningioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The WHO grade (2007 classification), Ki67-MIB1, progesterone receptor expression, and histological subtype were reexamined and correlated to the meningioma location, classified as medial skull base, lateral skull base, non-skull base, and spinal.
|
31637512 |
2019 |
Meningioma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
After GTR, 2.2% of meningiomas with MIB1 LI ≤ 7% recurred (1 of 45), compared with 38% with MIB1 LI > 7% (13 of 34; p < 0.001).
|
29624151 |
2018 |
Meningioma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
There was a statistically significant difference between the mean duration of symptoms, maximum dimension, and the MIB-1 LI of grade I and grade II meningiomas.
|
27841196 |
2018 |
Meningioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
MCM7 PI revealed significantly higher indices in recurrent meningiomas compared with non-recurrent meningiomas (p = 0.020), while mitotic index and MIB-1 PI did not reach statistical significance (p ≥ 0.547).
|
27868157 |
2017 |
Meningioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
DNA topoisomerase IIα and mitosin expression predict meningioma recurrence better than histopathological grade and MIB-1 after initial surgery.
|
28301542 |
2017 |
Meningioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Using immunohistochemistry, the expression of MIB-1 and survivin were determined as labeling indices (LIs) in tissue micro arrays from 160 human meningiomas.
|
28953948 |
2017 |
Meningioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Additionally, such biomarkers as Ki-67/MIB-1, progesterone receptors and phosphor-histone H3 were correlated with MG progression.
|
27375146 |
2016 |
Meningioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We performed fluorescence in-situ hybridization for 1p36 and 14q32, and immunohistochemistry for progesterone receptor (PR), p53 and MIB-1 on 84 meningiomas.
|
25237942 |
2014 |
Meningioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, COX-2 expression was significantly correlated with MIB-1 labeling index for all 76 cases of meningioma (P = 0.0075), suggesting tumor promotion by COX-2 in meningioma progression.
|
23250387 |
2014 |
Meningioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We evaluated retrospectively monotonous sheeting, necrosis, hypercellularity, nuclear pleomorphism, small cell changes, brain invasion, mitosis, mast cells, psammoma bodies, MIB-1 labeling index (MIB-1 LI) and histological grade of 230 primary meningioma tumors according to the latest World Health Organization (WHO) classification.
|
24398011 |
2014 |
Meningioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, the level of RACGAP1 expression mRNA was positively correlated with MIB-1 labeling index in different meningiomas tissue (r(2) = 0.3237, P = 0.0007).
|
23525949 |
2013 |
Meningioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The expression of COX-2, gamma-catenin, Topoisomerase IIa, VEGF and MIB-1 was significantly higher in the cohort of recurrent meningiomas.
|
20054806 |
2010 |
Meningioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Eighty-two specimens of human meningiomas were obtained for immunohistochemical analysis with anti-GnRH, anti-GnRH-R, anti-PR, anti-ER, and anti-Ki-67 (MIB-1) antibodies, and for RT-PCR analysis of the mRNA expressions of GnRH and GnRH-R. Correlations of GnRH and GnRH-R with PR, ER, Ki-67, and clinical features such as age, sex, tumor grade, and tumor histology were assessed.
|
18980792 |
2009 |
Meningioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Implicating chromosomal aberrations with meningioma growth and recurrence: results from FISH and MIB-I analysis of grades I and II meningioma tissue.
|
18060363 |
2008 |
Meningioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
High-proliferative atypical meningiomas had an elevated median MIB-1 labeling index and a greater frequency of copy number aberrations (CNAs) compared to low-proliferative atypical meningiomas.
|
17937814 |
2007 |
Meningioma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Pal expression was mostly altered in grades II and III meningiomas (P = .000014) and meningiomas with high MIB-1 values (P = .001).
|
16040297 |
2005 |
Meningioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The MIB-1 index was 11% in the meningioma and <1% in the MA, indicating increased proliferative activity in the meningioma.
|
11826364 |
2002 |
Meningioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The MIB-1 proliferation index was significantly higher in the meningiomas expressing ST3 (Student t test: P < 0.001).
|
11857311 |
2002 |
Meningioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
When compared with several published studies of sporadic meningiomas, the MIB-1 index in NF2-associated meningiomas was not higher.
|
10850863 |
2000 |
Meningioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
MIB-1 immunostaining was used to detect proliferative potentials of meningiomas.
|
10071687 |
1999 |
Meningioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In order to characterize factors that may influence this behavior, we chose to compare MIB-1 labeling index (LI) and telomerase RNA localization (hTR) in papillary meningiomas, meningiomas, and atypical meningiomas.
|
10845390 |
1999 |
Meningioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The MIB-1 PI values of the early recurrent meningiomas were higher than those of nonrecurrent meningiomas, suggesting that MIB-1 PI is very important for biological and histopathological analyses and prediction of the future recurrence of meningiomas.
|
9879462 |
1998 |
Meningioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The comparison of MIB-SI between the tumors with (2.3 +/- 0.6%) and without (1.6 +/- 0.3%) chromosomal aberrations demonstrated a trend towards an increased MIB-SI in meningiomas with chromosomal aberrations (p < 0.07) by unpaired Student's t-test.
|
9785589 |
1998 |